scispace - formally typeset
D

Deborah M. Gordon

Researcher at Stanford University

Publications -  214
Citations -  24621

Deborah M. Gordon is an academic researcher from Stanford University. The author has contributed to research in topics: Foraging & Pogonomyrmex. The author has an hindex of 64, co-authored 202 publications receiving 23145 citations. Previous affiliations of Deborah M. Gordon include Santa Fe Institute & Carnegie Endowment for International Peace.

Papers
More filters
Journal ArticleDOI

Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control

TL;DR: It is shown that sympathetic and parasympathetic nervous activity make frequency-specific contributions to the heart rate power spectrum, and that renin-angiotensin system activity strongly modulates the amplitude of the spectral peak located at 0.04 hertz.
Journal Article

Assessment of autonomic function in human by heart rate spectral analysis

TL;DR: In this paper, the authors assessed spontaneous heart rate fluctuations by use of autonomic blocking agents and changes in posture, and found that low-frequency fluctuations (below 0.12 Hz) in the supine position are mediated entirely by the parasympathetic nervous system.
Journal ArticleDOI

Assessment of autonomic function in humans by heart rate spectral analysis

TL;DR: In this paper, the authors assessed spontaneous heart rate fluctuations by use of autonomic blocking agents and changes in posture, and found that low-frequency fluctuations (below 0.12 Hz) in the supine position are mediated entirely by the parasympathetic nervous system.
Journal ArticleDOI

Hemodynamic regulation: investigation by spectral analysis

TL;DR: It is found that respiratory frequency fluctuations in HR are parasympathetically mediated and that blood pressure fluctuations at this frequency result almost entirely from the direct effect of centrally mediated HR fluctuations, and the sympathetic nervous system appears to be too sluggish to mediate respiratory frequency variations.
Journal ArticleDOI

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.

TL;DR: This study proves that ARV-771, a small-molecule pan-BET degrader based on proteolysis-targeting chimera (PROTAC) technology, demonstrates dramatically improved efficacy in cellular models of CRPC as compared with BET inhibition.